Legend Capital took part in a $46.3m series B-plus round for enzyme product developer Yeasen Biotechnology two months after the latter closed its series B round.

Based on research at Institute for Cancer Research, Nuvectis Pharma is working on precision medicines for cancer.

Ferrovial and Mitsui Fudosan helped mobility platform developer Maas Global hike its latest round to nearly $46m while automotive technology developer Visic Technologies raised $35m.

The $3bn merger of meditation app developer Headspace and digital mental health services provider Ginger would present a new path for a plethora of corporate investors.

Optum has signed on to the fight against obesity, backing the telemedicine programme provider and taking its overall funding to over $127m.

M12 helped cybersecurity software producer Hunters raise $30m while Scor and Transamerica are set to exit patient monitoring software developer 100Plus.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Bristol Myers Squibb returned to reinvest in the cardiac disease therapy developer having backed its 2017 series A round with Boehringer Ingelheim.

Utah spinout Techcyte has received $21m in funding, three and a half years after its series A round.

Hannover Medical School spinout Cardior has welcomed both new and existing backers, such as Bristol Myers Squibb, for a series B round led by Inkef Capital.